Lead electrode incorporating extracellular matrix

• US 7,981,065 B2
• Filed: 12/20/2004
• Issued: 07/19/2011
• Est. Priority Date: 12/20/2004
• Status: Active Grant

• Current Assignee: Cardiac Pacemakers Incorporated (Boston Scientific Corporation)
• Original Assignee: Cardiac Pacemakers Incorporated (Boston Scientific Corporation)
• Inventors: Westlund, Randy, Ross, Jeffrey
• Primary Examiner(s): Brown; Michael A.
• Application Number:
  US11/017,238
• Publication Number:
  US 20060136027A1
• Time in Patent Office: 2,402 Days
• Field of Search: 601136-137, 607/51, 607/73
• US Class Current: 601/136
• CPC Class Codes: A61N 1/0575 with drug delivery
• CPC Class Codes: A61N 1/0587 Epicardial electrode systems; Endocardial electrodes piercing the pericardium
• CPC Class Codes: A61N 1/059 Anchoring means

Abstract

Implantable devices containing extracellular matrix and methods of using the devices are provided.

Claims

1. A method comprising affixing an isolated extracellular matrix (ECM) sheet including isolated ECM having a native three dimensional microstructure to an electrode in an amount effective to inhibit fibrotic capsule formation and/or enhance excitable tissue formation around a lead comprising the electrode after implantation of the lead.

2. The method of claim 1, wherein the isolated ECM is affixed to the surface of the electrode.

3. The method of claim 1, wherein donor cells and/or one or more cytokines are contacted with the isolated ECM sheet after affixing the isolated ECM to the electrode.

4. The method of claim 3, wherein one cytokine is G-CSF, SCF, HGF or IGF.

5. The method of claim 1, wherein donor cells and/or one or more cytokines are contacted with the isolated ECM sheet prior to affixing the isolated ECM to the electrode.

6. The method of claim 5, wherein one cytokine is G-CSF, SCF, HGF or IGF.

7. The method of claim 3 or 5, wherein the donor cells are stem cells.

8. The method of claim 3 or 5, wherein the donor cells are autologous cells.

9. The method of claim 3 or 5, wherein the donor cells are bone marrow-derived cells.

10. The method of claim 3 or 5, wherein the donor cells are mesenchymal cells.

11. The method of claim 1, wherein the ECM is isolated from small intestine submucosa or urinary bladder submucosa.

12. The method of claim 1 wherein the isolated ECM is xenogeneic.

13. The method of claim 1, wherein the isolated ECM is decellularized.

14. The method of claim 1, wherein the isolated ECM is allogeneic.

15. The method of claim 1, further comprising affixing an isolated ECM sheet to a portion of a surface of the lead body.

16. The method of claim 1 wherein the isolated ECM sheet has a thickness of approximately 50 microns to 80 microns.

17. The method of claim 1 wherein the isolated ECM sheet comprises a rinsed and mechanically delaminated portion of small intestine or urinary bladder.